ClinicalTrials.gg
WithdrawnNCT05205252ARIAUpdated Aug 15, 2023

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

A Phase 1/2 interventional study of Tazemetostat and Tafasitamab in Relapsed Hematologic Malignancy and Refractory Hematologic Malignancy, sponsored by Epizyme, Inc.. Withdrawn at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-15.

Sponsored by Epizyme, Inc. (part of Ipsen) · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Epizyme Inc. has revised the Tazemetostat development strategy and made the decision to terminate the hematological malignancies basket trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Enrollment
629th of 658
0 · median 40
Started
2021
with 74 others
Phase 1/2
81 of 821
16 open now
Registered
646th of 821
by date

Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 629th largest by enrollment of the 658 interventional ones that give a count, is one of 75 that started in 2021, is one of 81 in phase 1/2, and was the 646th registered.

Hematologic Neoplasms

1,444 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 821 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This trial will study how safely the tazemetostat works with other therapies in various hematological malignancies. Hematologic malignancies are cancers that most often begin in the bone marrow or lymph nodes where blood precursors are produced.

They are often called blood cancers and fall into three categories: leukemia, lymphoma and myeloma.

Tazemetostat has been found to be a safe and effective drug that works in patients with follicular lymphoma where the disease has come back after treatment (known as relapsed) and when other treatment no longer works (known as refractory).

Combining tazemetostat with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response.

Read the detailed description

This phase 1b/2 trial studies how safely the EZH2 inhibitor tazemetostat works with other therapies in various hematological malignancies. Tazemetostat has been found to be a safe and effective drug that works in patients with relapsed refractory (R/R) follicular lymphoma. Giving tazemetostat in combination with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response.

03

Conditions studied

  • Relapsed Hematologic Malignancy
  • Refractory Hematologic Malignancy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status 0 to 1 for Phase 1b and status 0 to 2 for Phase 2
  2. Must have documented , refractory, or progressive disease after 2 with systemic therapy
  3. Demonstrate adequate organ function
  4. Negative test results for acute or chronic virus (HBV) infection, virus (HCV) and
  5. No ongoing reactions to prior anticancer treatments
  6. Willingness to follow pregnancy precautions and register into the mandatory REMS program in lenalidomide and pomalizdomide arms

Exclusion criteria

Exclusion Criteria:

  1. Presence or history of central nervous system involvement by lymphoma
  2. Less than minimum of prior anticancer therapy as specified by the protocol
  3. Prior haematopoietic stem cell transplantation
  4. History of solid organ transplant
  5. Major surgery within 4 weeks of the start of study drug.
  6. Significant cardiac or cardiovascular impairment as specified by protocol
  7. Venous thrombosis or pulmonary embolism within the last 3 months before starting tazemetostat
  8. History of any bleeding disorder, peptic ulcer disease, or significant bleeding within the last 1 month prior to enrollment
  9. Are unable to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition
  10. Patients with known active infection, or reactivation of a latent infection, as specified by the protocol
  11. Known sensitivity or allergy to the study medications
  12. Unwilling to refrain from eating or drinking grapefruit juice, Seville oranges, and grapefruits while on study
  13. Prior exposure to tazemetostat
  14. Any condition that places the subject at unacceptable risk if he/she were to participate in the study or that confounds the ability to interpret data from the study.
  15. Prior history of myeloid or T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL)
  16. For patients with DLBCL in Arm 1 (tazemetostat plus tafasitamab plus lenalidomide) or Arm 2 (tazemetostat plus lenalidomide):

    • Prior exposure to lenalidomide
  17. For patients with MCL in Arm 3 (tazemetostat plus acalabrutinib):

    • Prior exposure to a BTKi
    • Medical condition that would make treatment with a BTKi not reasonable (e.g. allergy to BTKi or mutations known not to respond to BTKi treatment or subjects unable to be transitioned off of proton pump inhibitors)
  18. For patients with MM in Arm 4:

    • Prior exposure to pomalidomide
    • Untreated or impending spinal cord compression in subjects
  19. For patients with FL in Arm 5:

    • Grade 3b, mixed histology, or FL that has histologically transformed to DLBCL.
    • History of significant neurological disorders, hemophagocytic lymphohistiocytosis (HLH), chronic active Epstein-Barr virus (EBV) infection, progressive multifocal leukoencephalopathy (PML), lung disease (ILD), drug-induced pneumonitis, pneumonitis, and/or history of severe autoimmune disease
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Arm 1-Tazemetostat plus tafasitamab-cxix (CD19 Ab)/lenalidomide

    Participants with R/R, diffuse large B-cell lymphoma (DLBCL) will receive tazemetostat, tafasitamab, and lenalidomide for approximately 1 year. After approximately 1 year, participants will receive tazemetostat and tafasitamab.

    Drug: Tazemetostat · Drug: Tafasitamab · Drug: Lenalidomide

  • Active comparator
    Arm 2-Tazemetostat plus lenalidomide

    Participants with R/R DLBCL will receive tazemetostat and lenalidomide for approximately 1 year. After approximately 1 year, participants will receive tazemetostat alone.

    Drug: Tazemetostat · Drug: Lenalidomide

  • Active comparator
    Arm 3- Tazemetostat plus BTKi (acalabrutinib)

    Participants with R/R mantle cell lymphomawill (MCL) will receive tazemetostat and acalabrutinib for the entire study.

    Drug: Tazemetostat · Drug: Acalabrutinib · Drug: Hyaluronidase-Fihj

  • Active comparator
    Arm 4-Tazemetostat plus CD38 mAbPD (daratumumab/pomalidomide/dexamethasone)

    Participants with R/R multiple myelomawill (MM) will receive tazemetostat, daratumumab, pomalidomide, and dexamethasone for the entire study. Daratumumab may be given intravenously or subcutaneously during this study.

    Drug: Tazemetostat · Drug: Daratumumab (Intravenously) · Drug: Daratumumab (Subcutaneously) · Drug: Pomalidomide · Drug: Dexamethasone 20mg

  • Active comparator
    Arm 5- Tazemetostat plus CD20/CD3 BsAb (mosunetuzumab)

    Participants with R/R follicular lymphoma will receive tazemetostat and mosunetuzumab for approximately 1 year. After approximately 1 year, participants will receive tazemetostat alone.

    Drug: Tazemetostat · Drug: Mosunetuzumab

Interventions

  • Orally, twice daily in continuous 28-day cycles.

    Also known as: IPN60200

  • Intravenously, 12 mg/kg, once daily on Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle. Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.

  • Orally, 10 mg or 20 mg based on kidney function, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles.

  • Orally, 100 mg, twice daily.

    Also known as: Bruton tyrosine kinase inhibitor

  • Intravenously, 16 mg/kg actual body weight, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.

  • Subcutaneously, step-up doses on Cycle 1 Days 1 (5 mg), 8 (45 mg) and 15 (45 mg) and then 45 mg from Cycle 2 through 12 on Day 1 of the 28-day cycle.

  • Subcutaneously, 1800 mg, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.

  • Subcutaneously, 30,000 units, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.

  • Orally, 4 mg, once daily on Days 1 to 21 of continuous 28-day cycles.

  • Orally, 20 mg or 40 mg, once daily on Days 1, 8, 15, and 22 of continuous 28-day cycles.

06

What researchers measure

Primary outcomes

  1. Phase 1b: Recommended Phase 2 Dose (RP2D) of tazemetostat in combination with each partner drug

    The safety and tolerability of tazemetostat in combination with each partner drug in participants with R/R malignancies will be evaluated. RP2D of tazemetostat for further evaluation in phase 2 will be selected as assessed by the occurrence of treatment-emergent dose-limiting toxicities (DLTs) and adverse events (AEs).

    Time frame: Evaluated for DLTs during the first 28-day cycle. The RP2D for Phase 2 for each arm will be selected at the end of that arm's experience in Phase 1b

  2. Phase 2: Objective Response Rate (ORR)

    Overall response rate is defined as proportion of participants with a best response of at least partial remission (including partial remission and complete remission for participants with non-Hodgkin lymphoma in Arms 1, 2, 3, or 5 or partial remission, complete remission, stringent complete response, or very good partial response).

    Time frame: Time from the date of first dose of study drug to the time of response, assessed up to 24 months.

Secondary outcomes

  1. Phase 2: Progression Free Survival (PFS)

    Progression free survival is defined as the time from randomization into the study to the first observation of documented disease progression or death due to any cause.

    Time frame: Up to 24 months.

  2. Time to response (TTR)

    Defined as the time from the first dose of study drug to the earliest date of CR or PR per Lugano Classification (Arms 1, 2, 3, and 5) or sCR, CR, VGPR, or PR per IMWG 2016 criteria (Arm 4) as assessed by Investigator review.

    Time frame: Up to 24 months

  3. Phase 2: Duration of Response (DOR)

    Duration of response is defined as the time from the initial response (at least partial remission) to documented disease progression.

    Time frame: Up to 24 months

  4. Phase 2: Disease control rate (DCR)

    Defined as the percentage of participants who achieve complete response (CR), partial response (PR), or stable disease per Lugano Classification (Arms 1, 2, 3, or 5) or stringent complete response (sCR), CR, very good partial response (VGPR), PR, or stable disease per IMWG 2016 criteria (Arm 4) at 6 months on study treatment, as assessed by Investigator review.

    Time frame: Up to 24 months

  5. Phase 2: Overall Survival (OS)

    Overall survival is defined as the time from the first dose of study drug to date of death due to any cause.

    Time frame: Up to 24 months

  6. Time to next treatment (TTNT)

    Defined as the time from the first dose of study drug to the start of subsequent anticancer therapy

    Time frame: Up to 24 months

  7. Percentage of participants with Treatment Emergent Adverse Event (TEAEs)

    An Adverse Event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 24 months

  8. Percentage of participants with clinically significant changes in laboratory parameters

    Percentage of participants with clinically significant changes in laboratory parameters including, hematology, serum chemistry, coagulation and urinalysis will be reported. The clinical significance will be evaluated by the investigator.

    Time frame: Up to 24 months

07

Study locations

3 sites
  • California Cancer Associates For Research And Excellence, cCARE
    Santa Fe, California 92024, United States
  • Central Care Cancer Center
    Bolivar, Missouri 65613, United States
  • Astera Cancer Center
    East Brunswick, New Jersey 08816, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jul 2023, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2021
First posted
Jan 25, 2022
StartActual
Dec 22, 2021
Primary completionActual
Jul 5, 2023
CompletionActual
Jul 5, 2023
Last update
Aug 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05205252
Lead sponsor
Epizyme, Inc.
Responsible party
Sponsor
First posted
Jan 25, 2022
Start date
Dec 22, 2021
Primary completion
Jul 5, 2023
Completion
Jul 5, 2023
Last update
Aug 15, 2023

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tafasitamab · Lenalidomide · Acalabrutinib · Daratumumab · Mosunetuzumab · Hyaluronidase (human recombinant) · Pomalidomide · Dexamethasone

Start the discussion